United Therapeutics agreed to buy Thymmune Therapeutics in a $140 million upfront deal, with up to $160 million in milestones tied to clinical and regulatory progress through 2031. Thymmune’s preclinical program converts human induced pluripotent stem cells into thymic cells intended to restore T-cell function after thymic decline. The lead asset, THY-100, targets congenital athymia, a rare condition with rapid early mortality in natural history cohorts. United highlighted the platform’s potential to expand beyond athymia into immune-mediated diseases and broader transplant-tolerance and longevity applications if early proof-of-concept holds.